MYD88 and Sepsis: In light of the present findings, the development and validation of new approaches for neonatal sepsis treatment are recommended, such as the potential use of TLR-pathway antagonists/inhibitors to limit the TLRs association with MyD88 preferentially and reduces the NFKB1 activity and/or IL68,39–41.